New chemo-free combo targets stubborn lymphoma
NCT ID NCT07477366
First seen Mar 29, 2026 · Last updated May 06, 2026 · Updated 4 times
Summary
This phase 2 study tests a chemotherapy-free combination of two investigational drugs (CD19 t-haNK and NAI) plus the standard drug rituximab in 20 adults with relapsed or refractory B-cell indolent non-Hodgkin lymphoma. The goal is to see how well the treatment shrinks tumors and how safe it is. Participants must be between 18 and 75 years old and have certain types of lymphoma that have not responded to prior therapy.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED B-CELL NON-HODGKIN LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.